Compare NUVL & TTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | TTEK |
|---|---|---|
| Founded | 2017 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 7.9B |
| IPO Year | 2021 | 1995 |
| Metric | NUVL | TTEK |
|---|---|---|
| Price | $123.50 | $29.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 3 |
| Target Price | ★ $134.75 | $44.00 |
| AVG Volume (30 Days) | ★ 4.2M | 3.9M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $2,964,148,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,239.49 | $6.43 |
| P/E Ratio | ★ N/A | $37.42 |
| Revenue Growth | N/A | ★ 7.66 |
| 52 Week Low | $71.14 | $25.81 |
| 52 Week High | $123.69 | $43.14 |
| Indicator | NUVL | TTEK |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 55.28 |
| Support Level | $97.99 | $26.98 |
| Resistance Level | $123.62 | $34.64 |
| Average True Range (ATR) | 0.58 | 0.93 |
| MACD | 0.66 | 0.20 |
| Stochastic Oscillator | 99.45 | 87.28 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.